http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
호알칼리성 Bacillus sp. No. 4의 Cyclodextrin Glycosyltransferase에 의한 Glycosyl Sucrose의 생산과 저충치성 당으로서의 응용
손천배,유미경,김명희,문숙경 충남대학교부설 생명공학연구소 1992 생물공학연구지 Vol.2 No.-
Action of a cyclodextrin glycosyltransferase (CGTase) produce from alkalophilic Bacillus sp. No. 4 was studied in a solution containing starch and sucrose to prepare glycosyl sucrose syrup with good sweetness and antidecaying properties of teeth. In the initial stage of the reaction the CGTase produced cyclodextrin, however, the cyclodextrin disappeared and glycosyl sucrose was formed with the lapse of reaction time. The best proportion of sucrose to starch for prodution of glycosyl sucrose was about 1 : 1. The optimum pH and temperature of the coupling reaction was pH 6.0 and 60℃, respectively. Main composition of glycosyl sucrose syrup prepared with 20% starch and 20% sucrose was sucrose 18%, glucosyl sucrose (G_2F) 15.3% and amltosyl sucorse (G_3F) 11.3%. And glucose, maltose and maltotriose were produced very little. Smaller amounts of acid and insoluble glucan were formed in the syrup by Streptococcus mtans OMZ176 than in the sucrose. Therefore, the prepared glycosyl sucrose sucrose syrup is expected to prevent teeth from decaying.
Cheon, Jae Hee,Kim, Eun Soo,Shin, Sung Jae,Kim, Tae Il,Lee, Kang Moon,Kim, Sang Woo,Kim, Joo Sung,Kim, You Sun,Choi, Chang Hwan,Ye, Byong Duk,Yang, Suk-Kyun,Choi, Eun Hee,Kim, Won Ho American College of Gastroenterology 2009 The American journal of gastroenterology Vol.104 No.10
<P>OBJECTIVES: It is difficult to diagnose intestinal Behçet's disease (BD) due to various extraintestinal manifestations emerging at different time points in the disease course and a lack of reliable diagnostic criteria. We conducted this study to develop and validate novel diagnostic criteria for intestinal BD. METHODS: Experts from three universities generated the preliminary diagnostic criteria for intestinal BD, and a consensus was reached using a modified Delphi method with 13 gastroenterologists participating. To validate the criteria, we recruited 12,850 consecutive patients who underwent colonoscopic examinations between January 2000 and December 2006 at Severance Hospital, Yonsei University, Seoul, Korea. RESULTS: The novel diagnostic criteria were developed on the basis of two aspects: colonoscopic findings and extraintestinal manifestations. Of the 12,850 patients, 280 with ileocolonic ulcers were enrolled for validation. At the time of initial colonoscopic examinations, patients were categorized for BD status into 4 groups: definite (84 patients), probable (67), suspected (15), and nondiagnostic (114). At the end of the follow-up period (mean, 50.9+/-25.7 months), intestinal BD was confirmed in 145 patients (51.8%)-84 (100%) from the definite group, 49 (73.1%) from the probable group, 10 (66.7%) from the suspected group, and 2 (1.8%) from the nondiagnostic group. The overall sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the diagnosis probability of these criteria were 98.6, 83.0, 86.1, 98.2, and 91.1%, respectively. CONCLUSIONS: These newly proposed, simple criteria might be useful in diagnosing intestinal BD, especially in patients with ileocolonic ulcers who do not fully satisfy the diagnostic criteria of systemic BD.</P>
Hepatitis B Reactivation among Chronic Hepatitis C Patients Treated with Direct Acting Antivirals
( Hee Yeon Kim ),( Chang Wook Kim ),( Jin Ah Kim ),( Mi Ju Cheon ),( Chan Ran You ),( Sang Wook Choi ),( Se Hyun Cho ),( Joon-Yeol Han ),( Do Seon Song ),( U Im Chang ),( Jin Mo Yang ),( Sung Won Lee 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: This study aimed to investigate hepatitis B virus (HBV) reactivation among hepatitis C virus (HCV) infected patients treated with oral direct acting antiviral (DAA) therapy in areas endemic for HBV in Korea. Methods: A total of 821 HCV-infected patients receiving oral DAA therapy from March 2015 to November 2016 were evaluated. Serum HBV DNA and HCV RNA was regularly assessed during and after DAA treatment in patients with HBV-HCV coinfection. HBV virological reactivation was defined as a >1 log increase in HBV DNA from baseline or a reappearance of HBV DNA for those with baseline undetectable HBV DNA. Clinical reactivation was defined as a serum alanine aminotransferase level ≥3-fold over the upper limit of normal or > 100 U/L. Results: Prior to DAA therapy 95.8% (787/821) had HBsAg testing and 1.7% (13/787) were positive. HBV virological reactivation was found in 7 (53.8%) of the 13 patients. HBV-related clinical reactivation was not observed in our cohort. Conclusions: For HBV-HCV co-infected patients, the risk of HBV virological reactivation was present after oral DAA treatment for HCV infection. Monitoring the HBV DNA level during oral DAA therapy for HCV infection is warranted.
( Hee Yeon Kim ),( Chang Wook Kim ),( Jin Ah Kim ),( Mi Ju Cheon ),( Chan Ran You ),( Sang Wook Choi ),( Do Seon Song ),( U Im Chang ),( Jin Mo Yang ),( Sung Won Lee ),( Hae Lim Lee ),( Nam Ik Han ),( 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: This study aimed to assess the efficacy of tenofovir (TDF) monotherapy in lamivudine (LAM)-resistant chronic hepatitis B (CHB) patients with a complete virological response to LAM plus adefovir (ADV). Methods: This is an investigator initiated open label, randomized controlled, non-inferiority trial. LAM-resistant CHB patients on LAM plus ADV therapy with undetectable hepatitis B virus (HBV) DNA were randomized (1:1) to TDF or LAM plus ADV and followed with serum biochemistry and HBV DNA every 12 weeks for 96 weeks. The primary endpoint was the proportion of patients with sustained undetectable HBV DNA at week 48. Results: A total of 76 CHB patients including 26 compensated cirrhosis were enrolled in this study. Thirty-eight patients were randomized to TDF and 38 patients to LAM plus ADV arm. There were no significant differences between two groups in baseline characteristics. Three (7.9%) patients in LAM/ADV group and 7 (18.4%) patients in TDF group were HBeAg-positive. Three patients (2 in LAM/ADV group and 1 in TDF group) dropped out of the study before the 48-week follow-up. Two patients achieved HBsAg seroconversion in LAM/ADV group (2/38, 5.3%). HBeAg loss rate at week 48 was 33.3% (1/3) in LAM/ADV group and 14.3% (1/7) in TDF group. The proportion of patients with sustained complete virological response at week 48 was not significantly different between two groups by per protocol analysis (100% vs 100%) as well as intention-to-treat analysis (94.7% in LAM/ADV group vs 97.2% in TDF group). Conclusions: Switching to TDF monotherapy showed a comparable efficacy to continuing combination therapy in LAM-resistant CHB patients with undetectable HBV DNA to LAM plus ADV combination therapy.
( Hee Yeon Kim ),( Chang Wook Kim ),( Jin Ah Kim ),( Mi Ju Cheon ),( Chan Ran You ),( Sang Wook Choi ),( Do Seon Song ),( U Im Chang ),( Jin Mo Yang ),( Sung Won Lee ),( Hae Lim Lee ),( Nam Ik Han ),( 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: This study aimed to investigate the efficacy of tenofovir (TDF) monotherapy in multiple drug-resistant chronic hepatitis B (CHB) patients with a complete virological response to TDF plus entecavir (ETV). Methods: This is an investigator initiated open label, randomized controlled, non-inferiority trial. Multiple drug-resistant CHB patients on TDF plus ETV therapy with undetectable hepatitis B virus (HBV) DNA were randomized (1:1) to TDF or TDF plus ETV and followed with serum biochemistry and HBV DNA every 12 weeks for 96 weeks. The primary endpoint was the proportion of patients with sustained undetectable HBV DNA at week 48. Results: A total of 50 CHB patients including 9 compensated cirrhosis were enrolled in this study. Twenty-five patients were randomized to TDF and 25 patients to TDF plus ETV arm. Baseline characteristics were not statistically different between two groups. Thirteen (52%) patients in TDF group and 13 (52%) patients in TDF/ETV group were HBeAg-positive. One patient in TDF group dropped out of the study before the 48-week follow-up. The proportion of patients with sustained complete virological response at week 48 was not significantly different between two groups by per protocol analysis (100% vs 100%) as well as intention-to-treat analysis (100% in TDF group vs 96% in TDF/ETV group). Conclusions: Switching to TDF monotherapy showed a comparable efficacy to continuing combination therapy in multiple drug-resistant CHB patients with undetectable HBV DNA to TDF plus ETV combination therapy.
( You Sun Kim ),( Young Ho Kim ),( Joo Sung Kim ),( Seong Yeon Jeong ),( Soo Jeong Park ),( Jae Hee Cheon ),( Byong Duk Ye ),( Sung Ae Jung ),( Young Sook Park ),( Chang Hwan Choi ),( Kyeung Ok Kim ) 대한소화기학회 2014 Gut and Liver Vol.8 No.6
Background/Aims: Cytomegalovirus (CMV) reactivations are frequently observed in patients with active ulcerative colitis (UC), and ganciclovir therapy is effective in patients with steroid-refractory UC. This study aimed to determine the longterm outcomes of CMV reactivation and the long-term therapeutic efficacy of ganciclovir treatment. Methods: This retrospective multicenter study included a cohort of 72 patients with moderate-to-severe UC who were evaluated for CMV reactivation at the time of their initial UC flare. Colectomy, disease relapse, and the recurrence rate of CMV reactivation were investigated. Results: The mean duration of follow-up for the 72 patients was 43.16±19.78 months (range, 1 to 67 months). The cumulative colectomy (log-rank, p=0.025) and disease flare-up rates (log-rank, p=0.048) were significantly higher in the CMV-positive group. Of the 11 patients who were successfully treated with ganciclovir in the initial treatment, three patients (27.3%) experienced CMV reactivation, and six patients (54.5%) experienced poor outcomes, such as the need for colectomy or a steroid-dependent state. Conclusions: The patients who had CMV-reactivated UC showed poor outcomes at the long-term follow-up, and the long-term efficacy of ganciclovir therapy was marginal. Careful assessment is necessary for patients who exhibit evidence of CMV reactivation. (Gut Liver 2014;8:643-647)
( You Sun Kim ),( Young Seok Doh ),( Young Il Park ),( Jong Pil Im ),( Jae Hee Cheon ),( Byong Duk Ye ),( Ji Won Kim ),( Sung Noh Hong ),( Young Ho Kim ),( Joo Sung Kim ),( Dong Soo Han ),( Won Ho Kim 대한내과학회 2014 대한내과학회 추계학술발표논문집 Vol.2014 No.1
Background: Among the complications of CD, free perforation is the most debilitating complication. A higher incidence of perforation has been reported in Japan than in western countries. However, no large-scale studies concerning perforations in Korean CD patients have been conducted. Methods: The CrOhn`s disease cliNical NEtwork and CohorT (CONNECT) study was conducted in Korea; CD patients who were diagnosed between 1982 and 2008 were included in retrospective cohort. We investigated perforation sites, clinical features, and operation records. We analyzed the association between clinical features and perforation. Results: 1,382 patients were enrolled from the 32-center retrospective CD cohort and 88 patients (6.4%) with perforation were identified. The mean age of the patients with perforation was 31.8±13.0 years, which is significantly higher than the others (27.5±12.1 years)(p=0.04). Free perforation was the presenting sign of CD in 47 patients (53%) and developed after diagnosis in 41 patients (47%). Of 94 perforations from the 88 patients, 81 involved the ileum, 6 the jejunum, and 7 the colon, and 5 patients had perforations at multiple sites. By multivariate analysis, free perforation had a significant association with age over 30 years at diagnosis (OR 1.974, p = 0.008) and bowel stricture (OR 2.235, p = 0.001), but did not show any significant association with steroids, azathioprine, and infliximab. The mortality of patients with free perforation was higher (4.6%; RR = 7.72, p = 0.001) than that of patients without perforation (0.6%). Conclusions: The incidence of free perforation in Korean patients with CD was 6.4% and it was higher than that in western countries. Old age at diagnosis and bowel stricture are significant risk factors for free perforation. Early diagnosis of CD is therefore important in reducing free perforation.
( You Sun Kim ),( Min Jeong Na ),( Byong Duk Ye ),( Jae Hee Cheon ),( Jong Pil Im ),( Joo Sung Kim ) 대한소화기기능성질환·운동학회 2022 Gut and Liver Vol.16 No.6
The clinical course and prognosis of patients with elderly-onset Crohn’s disease (CD) remain unclear. This study aimed to analyze the clinical characteristics and outcomes of elderly-onset CD patients from the prospective CONNECT study cohort, a nationwide, multicenter cohort study of patients with CD in Korea. Among a total of 1,175 patients in the prospective CONNECT study cohort, 94 patients (Montreal age A3) were included and divided into two groups according to their age at diagnosis: the elderly-onset group (diagnosed with CD after 60 years of age, n=26, 67.54±6.7 years) and late adult-onset group (diagnosed as CD at age 41 to 59 years, n=68, 48.06±5.1 years). The elderly-onset group was characterized by a lower Crohn’s disease activity index at diagnosis (124.89±101.9 vs 189.55±128.6, p=0.023) and higher rates of previous anti-tuberculosis treatment (34.6% vs 4.4%, p<0.001) than the late adult-onset group. Compared with the late adult-onset group, the elderly-onset group showed a significantly less use of thiopurines (p=0.003), as well as anti-tumor necrosis factor-alpha agents (p=0.047). Additionally, the elderly-onset group was less likely to require bowel resection than the late adult-onset group (p=0.067), suggesting that elderly-onset CD patients in Korea appear to have more favorable clinical outcomes than late adult-onset CD patients. (Gut Liver 2022;16:995-1000)